

**Press release for immediate publishing, July 26, 2004**

## **Monica Caneman new board member of Orexo AB**

*Monica Caneman took up the post as board member of the fast growing pharmaceutical company Orexo AB on July 15, 2004. Monica Caneman previously worked for SEB, where she was employed for 15 years, the last four of which as vice president.*

Orexo is an Uppsala based pharmaceutical company, focussed on drug delivery. Orexo specializes in different types of tablet formulations. The sublingual formulation, which means that the patient puts a fast dissolving tablet under the tongue, is today one of the company's most important technological platforms.

“Monica Caneman has her background at SEB, where she, among other things, held several important positions in financing and marketing. She is represented on the boards of a great number of companies in various businesses, which gives her a wide competence and experience. This is an important asset for a company like Orexo, which is in the middle of a fast expansion phase”, said Zsolt Lavotha, newly appointed CEO of Orexo AB.

Monica Caneman is an economist and a graduate from Handelshögskolan in Stockholm. She is since 2002 a member of several boards, i.e. Investment AB Öresund, SJ and Schibsted ASA. In connection with the appointment of Monica Caneman as a board member, Erik Helgestrand and Ulo Langel, board members since 2001 and 2002, left their positions.

---

**For more information, please contact**

Zsolt Lavotha, President & CEO, Orexo AB  
+46 (0)18 780 88 12, e-mail: [zsolt.lavotha@orexo.se](mailto:zsolt.lavotha@orexo.se)

**Orexo AB** (publ) is a Swedish pharmaceutical company established in 1995 based in Uppsala. Orexo develops, documents and registers patented pharmaceutical products based on innovative and proprietary drug formulations. This is carried out through in-house development, licensing or co-development with partners.

[www.orexo.se](http://www.orexo.se)

